TARSUS PHARMACEUTICALS, INC.
Income Statement
| Line Item | FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|---|
| Revenue | — | $451.4M | $183.0M | $17.4M | $25.8M | $57.0M | $0 | — |
| Cost of Revenue | — | — | — | — | — | — | — | — |
| Gross Profit | — | — | — | — | — | — | — | — |
| Gross Margin | — | — | — | — | — | — | — | — |
| Operating Expenses | ||||||||
| Research & Development | — | $64.3M | $53.4M | $50.3M | $42.6M | $41.7M | $18.8M | $3.2M |
| SG&A Expense | — | $427.3M | $237.3M | $108.7M | $44.9M | $25.4M | $8.2M | $1.1M |
| Operating Income | — | $-71.0M | $-120.6M | $-143.2M | $-62.7M | $-12.2M | $-27.0M | $-4.3M |
| Operating Margin | — | -15.7% | -65.9% | -820.5% | -242.9% | -21.3% | — | — |
| Interest Expense | — | $8.9M | $7.8M | $3.3M | $2.2M | $0 | — | — |
| Pretax Income | — | $-64.4M | $-115.6M | $-135.9M | $-62.1M | $-13.8M | $-26.8M | — |
| Income Tax Expense | — | $2.1M | $0 | $0 | $-4.0K | $55.0K | $1.0K | $1.0K |
| Net Income | — | $-66.4M | $-115.6M | $-135.9M | $-62.1M | $-13.8M | $-26.8M | $-4.7M |
| Net Margin | — | -14.7% | -63.2% | -778.9% | -240.5% | -24.2% | — | — |
| EPS (Basic) | — | $-1.59 | $-3.07 | $-4.62 | $-2.52 | $-0.67 | $-1.44 | $-0.66 |
| EPS (Diluted) | — | $-1.59 | $-3.07 | $-4.62 | $-2.52 | $-0.67 | $-1.44 | $-0.66 |
| Shares Outstanding (Basic) | 42.6M | 41.8M | 37.6M | 29.4M | 24.6M | 20.6M | 18.6M | 7.9M |
| Shares Outstanding (Diluted) | 42.6M | 41.8M | 37.6M | 29.4M | 24.6M | 20.6M | 18.6M | 7.9M |
| Dividends Per Share | — | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |